CancerNCT00768976
Study of Patient Satisfaction With the Cancer Clinical Trial Experience
An observational study of Cancer, run by Summa Health System.
Trial summary
The primary objective of this study is to evaluate the quality of the clinical trial experience of cancer patients participating in cancer research studies through Summa Health System Hospitals Cancer Research Program by evaluating patient satisfaction regarding reasons for participating, facility, consent and… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cancer
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Oct 2008to May 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
Who may be able to join
- Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
- Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
Who cannot join
- Participant has withdrawn consent for clinical trial participation and/or follow up.
- Participant has a major medical illness that would prevent completion of the survey.
About this study
The primary objective of this study is to evaluate the quality of the clinical trial experience of cancer patients participating in cancer research studies through Summa Health System Hospitals Cancer Research Program by evaluating patient satisfaction regarding reasons for participating, facility, consent and treatment, personal issues and overall assessment.
The secondary objective of this study is to determine areas for improvement to make the patient's clinical trial experience a satisfying and positive journey.
- Conditions
- Cancer
- Keywords
- Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program., Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of surveys to determine if there are opportunities for performance and/or quality improvement projects.patient satisfaction regarding reasons for participating, facility, consent and treatment, personal issues and overall assessment.
Measured: Survey will be sent to subject 3 months after study registration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2008 (estimated)
- Study startOct 2008
- Primary completionMay 2012
- Study completionMay 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Summa Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joyce Neading, Summa Health System
- Investigators
- Joyce Neading, RHIT, CTR, Principal investigator, Summa Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00768976
- Sponsor's protocol ID
- Clinical trial experience
- Status last verified
- May 2012
- First submitted
- 7 Oct 2008
- Last updated
- 23 May 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Patient Satisfaction With the Cancer Clinical Trial Experience
- ClinicalTrials.gov ID
- NCT00768976
- Acronym / sponsor ID
- Clinical trial experience
- Conditions
- Cancer
- Keywords
- Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program., Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Summa Health SystemUniversity, hospital or other
- Study start
- Oct 2008
- Primary completion
- May 2012 (actual)
- Study completion
- May 2012 (actual)
- First posted
- 8 Oct 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate the quality of the clinical trial experience of cancer patients participating in cancer research studies through Summa Health System Hospitals Cancer Research Program by evaluating patient satisfaction regarding reasons for participating, facility, consent and treatment, personal issues and overall assessment.
The secondary objective of this study is to determine areas for improvement to make the patient's clinical trial experience a satisfying and positive journey.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
Key inclusion criteria (2 listed)
- Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
- Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
Key exclusion criteria (2 listed)
- Participant has withdrawn consent for clinical trial participation and/or follow up.
- Participant has a major medical illness that would prevent completion of the survey.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of surveys to determine if there are opportunities for performance and/or quality improvement projects.patient satisfaction regarding reasons for participating, facility, consent and treatment, personal issues and overall assessment.
Time frame: Survey will be sent to subject 3 months after study registration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2012.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joyce Neading, RHIT, CTR principal investigator
Summa Health System
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Summa Health System.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 May 2012. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of surveys to determine if there are opportunities for performance and/or quality improvement projects.patient satisfaction regarding reasons for participating, facility, consent and treatment, personal issues and overall assessment. (time frame: Survey will be sent to subject 3 months after study registration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2012.